Gaps, tensions, and conflicts in the FDA approval process: implications for clinical practice

Area of Science:

• Regulatory Science
• Pharmaceutical Policy
• Medical Device Oversight

Background:

• The Food and Drug Administration (FDA) plays a crucial role in ensuring the safety and efficacy of drugs and medical devices.
• However, the FDA's approval processes are subject to internal tensions, conflicts of interest, and potential limitations.

Purpose of the Study:

• To critically examine the limitations and challenges within the FDA's drug and device approval system.
• To inform healthcare professionals about potential issues regarding new drug and device efficacy, safety, and marketing.

Main Methods:

• Analysis of existing literature and reports concerning FDA approval processes.
• Review of identified limitations such as lack of comparative efficacy testing, inadequate post-marketing surveillance, and conflicts of interest.

Main Results:

• The FDA does not consistently compare competing drugs or mandate rigorous efficacy tests for new devices.
• Concerns exist regarding the adequacy of post-marketing surveillance and the influence of conflicts of interest on advisory committees.
• Pressure for rapid approvals may compromise thorough safety evaluations, and direct-to-consumer advertising can be misleading.

Conclusions:

• Physicians must exercise caution, recognizing that newer drugs may not outperform older ones and can have unforeseen side effects.
• Evidence for the efficacy of new devices is often less robust than for drugs, and cost-effectiveness is not a factor in FDA approval.
• Awareness of these limitations is essential for informed clinical decision-making and patient care.